

March 2, 2023

To: The Office of the Attorney General of Vermont

Via: Electronic Mail (AGO.DrugCosts@vermont.gov; AGO.highcostprescriptiondrugs@vermont.gov)

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637 (c)

On January 31, 2023 and pursuant to 18 V.S.A. § 4637 (b), Amgen Inc, USA (Amgen) submitted a notice of new drug introduction for the following:

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC
AMJEVITA (20 mg/0.4 mL prefilled syringe, 1 pk)	55513-0411-01	January 31, 2023	\$3,288.24
AMJEVITA (40 mg/0.8 mL prefilled syringe, 1 pk)	55513-0410-01	January 31, 2023	\$3,288.24
AMJEVITA (40 mg/0.8 mL Autoinjector, 1 pk)	55513-0400-01	January 31, 2023	\$3,288.24
AMJEVITA (40 mg/0.8 mL Autoinjector, 2 pk)	55513-0400-02	January 31, 2023	\$6,576.48
AMJEVITA (40 mg/0.8 mL Autoinjector, 1 pk)	72511-0400-01	January 31, 2023	\$1,557.59
AMJEVITA (40 mg/0.8 mL Autoinjector, 2 pk)	72511-0400-02	January 31, 2023	\$3,115.18

Amgen now provides the following additional information pursuant to 18 V.S.A § 4637 (c):

1. United States and international marketing and pricing plans used at launch:
 - There is a direct-to-consumer marketing plan for AMJEVITA. Efforts in the public domain consist of: (1) patient website www.AMJEVITA.com, (2) patient education brochures (1 brochure in print & digital form) and (3) emails for those patients that opt into communications & enroll in patient support. The purpose of the website is to educate patients on AMJEVITA (aligned to USPI), biosimilars, and patient support services. Patients can also enroll directly to patient support services via www.AMJEVITA.com. The purpose of the emails is to provide patients with important reminders following their being prescribed AMJEVITA such as to look out for a call from their specialty pharmacy call, education on how to inject AMJEVITA using the SureClick device or the pre-filled syringe and tips on how to stay on track with AMJEVITA.
 - Promotional activities to HCPs include the HCP website, www.AMJEVITAPro.com, printed resources, a national webinar program, email blasts and other digital resources in line with the AMJEVITA USPI. The purpose of these tools is to educate HCPs about the availability of the

therapy, clinical aspects including efficacy, safety, dosing and administration, along with applicable support services. AMJEVITA offers a sample program as well.

- Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles:
 - I. Pricing our products according to the value they deliver
 - II. Employs flexible pricing approaches to ensure patient access
- 2. Estimate Volume of Patients:
 - Amgen provides this report with its understanding of 18 V.S.A. §4637(d) and reserves all of its rights thereunder and otherwise.
- 3. Whether the FDA granted breakthrough therapy designation or priority review:
 - The FDA did not grant breakthrough therapy designation or priority review for AMJEVITA.
- 4. Date and price of acquisition:
 - Not Applicable

Amgen provides this report consistent with its understanding and interpretation of 18 V.S.A § 4637 and its provisions. In providing this report, Amgen does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Amgen or any of its affiliates, now or in the future. Amgen, on behalf of itself and its affiliates, expressly reserves all such rights.

Regards,

Pat Costello

Executive Director, US Value and Access Strategy

Amgen Inc, USA